Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.59 |
| ▸ | PGR | P06401 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6672982 | 1.00 | ESR1 (0.59) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL6672979 | 1.00 | ESR1 (0.59) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5124519 | 0.92 | ESR1 (0.68) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5124515 | 0.92 | ESR1 (0.68) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5124512 | 0.92 | ESR1 (0.68) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5069457 | 0.87 | ESR1 (0.76) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5069452 | 0.87 | ESR1 (0.76) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5069462 | 0.87 | ESR1 (0.76) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL1881240 | 0.83 | ESR1 (0.87) | ESR1ESR2PGR | |
| SCHEMBL1881237 | 0.83 | ESR1 (0.87) | ESR1ESR2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268389-B1 | HALOGENATED TRIPHENYLETHYLENE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6528681-B2 | 3-(4-(1-(4-fluorophenyl)-2-phenyl-but-1-enyl)phenyl)acrlic acid for example; for treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders | BRISTOL-MEYERS SQUIBB PHARMA COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20020013297-A1 | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013297-A1 | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators | GPER1, ESR1, PTGER1 | ESR1 2/4885ESR2 11/4885PGR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.